North Brunswick, NJ – According to filings with the U.S. Securities and Exchange Commission, BioAegis Therapeutics is raising $5,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Susan Levinson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About BioAegis Therapeutics

At BioAegis Therapeutics we are a clinical stage private company focused on developing therapies for infectious, inflammatory and degenerative diseases. Our programs capitalize on Evolutionary Wisdom with a natural protein, plasma gelsolin, which has fulfilled this role for vertebrates for millennia. Building upon IP and know-how licensed from Harvard Medical School, we are developing a portfolio of products based on repletion of the highly conserved, abundant human protein plasma gelsolin. The first product is in Phase 2 and follow on products are in development.

To learn more about BioAegis Therapeutics, visit http://bioaegistherapeutics.com/

Contact:
Susan Levinson, Chief Executive Officer
203-952-6373
slevinson@bioaegistherapeutics.com
https://www.linkedin.com/in/susanlevinson/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved